<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953743</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-C086-107</org_study_id>
    <nct_id>NCT02953743</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic&#xD;
      (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma&#xD;
      (HCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">December 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time at which the highest drug concentration occurs (tmax)</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC(0-t))</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum observed concentration at steady-state (Css,max )</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean minimum observed concentration at steady-state (Css,min)</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average steady-state concentration (Css,av)</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time at which the highest drug concentration occurs at steady-state (tss,max)</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ))</measure>
    <time_frame>Day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 2 at pre-dose; Day 8 at pre-dose; Day 15 at pre-dose, 0.5, 1, 2, 4, 6, and 8 hours; Day 16 at pre-dose; and Day 22 at pre-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 30 days after the administration of the last dose of study drug or up to approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Lenvatinib 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants weighing ≥ 60 kg will be enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants weighing &lt; 60 kg will be enrolled in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.</description>
    <arm_group_label>Lenvatinib 12 mg</arm_group_label>
    <arm_group_label>Lenvatinib 8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Participants must have confirmed diagnosis of unresectable Hepatocellular Carcinoma&#xD;
             (HCC) with any of the following criteria:&#xD;
&#xD;
               1. Histologically or cytologically confirmed diagnosis of HCC&#xD;
&#xD;
               2. Clinically confirmed diagnosis of HCC according to American Association for the&#xD;
                  Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or&#xD;
                  with chronic hepatitis B or C infection criteria&#xD;
&#xD;
          2. Participants categorized to stage B (not applicable for transarterial&#xD;
             chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC)&#xD;
             staging system&#xD;
&#xD;
          3. Adequate bone marrow function, defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/Liter (L)&#xD;
&#xD;
               2. Hemoglobin (Hb) ≥ 8.5 gram per deciliter (g/dL)&#xD;
&#xD;
               3. Platelet count ≥ 75 × 10^9/L&#xD;
&#xD;
          4. Adequate liver function, defined as:&#xD;
&#xD;
               1. Albumin ≥ 2.8 g/dL&#xD;
&#xD;
               2. Bilirubin ≤ 3.0 milligram per deciliter (mg/dL)&#xD;
&#xD;
               3. Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine&#xD;
                  aminotransferase (ALT) ≤ 5 × the upper limit of normal (ULN)&#xD;
&#xD;
          5. Adequate blood coagulation function, defined as international normalized ratio (INR) ≤&#xD;
             2.3&#xD;
&#xD;
          6. Adequate renal function defined as creatinine clearance &gt; 40 milliliter per min&#xD;
             (mL/min) calculated per the Cockcroft-Gault formula&#xD;
&#xD;
          7. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents,&#xD;
             defined as systolic BP ≤ 150 millimeter of mercury (mm Hg) and diastolic BP ≤ 90 mm Hg&#xD;
             at screening and no change in antihypertensive therapy within 1 week prior to the&#xD;
             registration.&#xD;
&#xD;
          8. Child-Pugh A (score 5-6)&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG)- performance status (PS) 0 or 1&#xD;
&#xD;
         10. Survival expectation of 12 weeks or longer after starting study drug&#xD;
&#xD;
         11. Males or females aged at least 18 years at the time of informed consent.&#xD;
&#xD;
         12. Females must not be lactating or pregnant at Screening or Baseline (as documented by a&#xD;
             negative beta-human chorionic gonadotropin [Beta-hCG] test with a minimum sensitivity&#xD;
             of 25 International Unit/Liter [IU/L] or equivalent units of beta-hCG). A separate&#xD;
             baseline assessment is required if a negative screening pregnancy test was obtained&#xD;
             more than 72 hours before the first dose of study drug.&#xD;
&#xD;
         13. All females will be considered to be of childbearing potential unless they are&#xD;
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age&#xD;
             group and without other known or suspected cause) or have been sterilized surgically&#xD;
             (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with&#xD;
             surgery at least one month before dosing).&#xD;
&#xD;
         14. Females of childbearing potential must not have had unprotected sexual intercourse&#xD;
             within 30 days before study entry and must agree to use a highly effective method of&#xD;
             contraception (eg, total abstinence, an intrauterine device, a double-barrier method&#xD;
             [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral&#xD;
             contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout&#xD;
             the entire study period and for 30 days after study drug discontinuation. If currently&#xD;
             abstinent, the participant must agree to use a double barrier method as described&#xD;
             above if she becomes sexually active during the study period or for 30 days after&#xD;
             study drug discontinuation. Females who are using hormonal contraceptives must have&#xD;
             been on a stable dose of the same hormonal contraceptive product for at least 4 weeks&#xD;
             before dosing and must continue to use the same contraceptive during the study and for&#xD;
             30 days after study drug discontinuation.&#xD;
&#xD;
         15. Male participants must have had a successful vasectomy (confirmed azoospermia) or they&#xD;
             and their female partners must meet the criteria above (ie, not of childbearing&#xD;
             potential or practicing highly effective contraception throughout the study period and&#xD;
             for 30 days after study drug discontinuation). No sperm donation is allowed during the&#xD;
             study period and for 30 days after study drug discontinuation.&#xD;
&#xD;
         16. Provide written informed consent&#xD;
&#xD;
         17. Willing and able to comply with all aspects of the protocol as judged by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Imaging findings for HCC corresponding to any of the following:&#xD;
&#xD;
               1. HCC with ≥50% liver occupation&#xD;
&#xD;
               2. Clear invasion into the bile duct&#xD;
&#xD;
               3. Portal vein invasion at the main portal branch (Vp4)&#xD;
&#xD;
          2. Participants who have received lenvatinib&#xD;
&#xD;
          3. Participants who have received any anti-cancer therapy (including surgery,&#xD;
             percutaneous ethanol injection, radio frequency ablation, transarterial [chemo]&#xD;
             embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy,&#xD;
             hormonal, any investigational drugs or radiotherapy) or any blood enhancing treatment&#xD;
             (including blood transfusion, blood products, or agents that stimulate blood cell&#xD;
             production, eg, granulocyte colony-stimulating factor [G-CSF]) within 28 days prior to&#xD;
             registration.&#xD;
&#xD;
          4. Participants who have not recovered from toxicities as a result of prior anticancer&#xD;
             therapy except alopecia and infertility. Recovery is defined as &lt; Grade 2 severity per&#xD;
             Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).&#xD;
&#xD;
          5. Significant cardiovascular impairment: history of congestive heart failure greater&#xD;
             than New York Heart association (NYHA) Class II, unstable angina, myocardial&#xD;
             infarction or stroke within 6 months of the first dose of study drug, or cardiac&#xD;
             arrhythmia requiring medical treatment at screening&#xD;
&#xD;
          6. Prolongation of Q wave and T wave interval corrected by the Fridericia formula (QTcF)&#xD;
             interval to &gt; 480 milli second (msec)&#xD;
&#xD;
          7. Gastrointestinal malabsorption, or any other condition in the opinion of the&#xD;
             investigator that might affect the absorption of lenvatinib&#xD;
&#xD;
          8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR&#xD;
             monitoring, eg, warfarin or similar agents. Treatment with low molecular weight&#xD;
             heparin and factor X inhibitors which do not require INR monitoring is permitted.&#xD;
             Antiplatelet agents are prohibited throughout the study.&#xD;
&#xD;
          9. Gastrointestinal bleeding event within 28 days prior to registration&#xD;
&#xD;
         10. Gastric or esophageal varices that require interventional treatment within 28 days&#xD;
             prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective&#xD;
             beta-blocker) is permitted.&#xD;
&#xD;
         11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to&#xD;
             registration&#xD;
&#xD;
         12. Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or&#xD;
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the&#xD;
             past 36 months from registration.&#xD;
&#xD;
         13. Any history of or current brain or subdural metastases&#xD;
&#xD;
         14. Participants having &gt; 1+ proteinuria on urine dipstick testing will undergo 24h urine&#xD;
             collection for quantitative assessment of proteinuria. Participants with urine protein&#xD;
             ≥ 1 gram (g)/24 hour (h) will be ineligible.&#xD;
&#xD;
         15. Surgical arterial-portal venous shunt or arterial-venous shunt.&#xD;
&#xD;
         16. Any medical or other condition that in the opinion of the investigator would preclude&#xD;
             participation in a clinical study&#xD;
&#xD;
         17. Human immunodeficiency virus (HIV) positive, or active infection requiring treatment&#xD;
             (except for hepatitis virus)&#xD;
&#xD;
         18. History of drug or alcohol dependency or abuse within approximately 2 years prior to&#xD;
             registration.&#xD;
&#xD;
         19. Any participant who cannot be evaluated by dynamic CT because of allergic reaction to&#xD;
             contrast agent of CT.&#xD;
&#xD;
         20. Major surgery within 3 weeks prior to registration or scheduled for surgery during the&#xD;
             study&#xD;
&#xD;
         21. Participant who has had a liver transplant.&#xD;
&#xD;
         22. Participants whose only tumor lesion(s) is in bone will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7080</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Pharmacokinetic study</keyword>
  <keyword>Chinese participants</keyword>
  <keyword>Unresectable Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

